JP2011520781A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520781A5
JP2011520781A5 JP2011503360A JP2011503360A JP2011520781A5 JP 2011520781 A5 JP2011520781 A5 JP 2011520781A5 JP 2011503360 A JP2011503360 A JP 2011503360A JP 2011503360 A JP2011503360 A JP 2011503360A JP 2011520781 A5 JP2011520781 A5 JP 2011520781A5
Authority
JP
Japan
Prior art keywords
cell
egf
ms4a12
activity
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011503360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520781A (ja
Filing date
Publication date
Priority claimed from EP08007109A external-priority patent/EP2108701A1/en
Application filed filed Critical
Publication of JP2011520781A publication Critical patent/JP2011520781A/ja
Publication of JP2011520781A5 publication Critical patent/JP2011520781A5/ja
Pending legal-status Critical Current

Links

JP2011503360A 2008-04-10 2009-03-30 治療、診断及び検査のためのｍｓ４ａ１２を伴う方法、及びｍｓ４ａ１２を標的とする剤 Pending JP2011520781A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08007109.5 2008-04-10
EP08007109A EP2108701A1 (en) 2008-04-10 2008-04-10 Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
PCT/EP2009/002309 WO2009124670A1 (en) 2008-04-10 2009-03-30 Methods involving ms4a12 and agents targeting ms4a12 for therapy, diagnosis and testing

Publications (2)

Publication Number Publication Date
JP2011520781A JP2011520781A (ja) 2011-07-21
JP2011520781A5 true JP2011520781A5 (cg-RX-API-DMAC10.html) 2012-05-24

Family

ID=39811474

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011503360A Pending JP2011520781A (ja) 2008-04-10 2009-03-30 治療、診断及び検査のためのｍｓ４ａ１２を伴う方法、及びｍｓ４ａ１２を標的とする剤

Country Status (8)

Country Link
US (1) US20110027297A1 (cg-RX-API-DMAC10.html)
EP (2) EP2108701A1 (cg-RX-API-DMAC10.html)
JP (1) JP2011520781A (cg-RX-API-DMAC10.html)
CN (1) CN101998992A (cg-RX-API-DMAC10.html)
AU (1) AU2009235746A1 (cg-RX-API-DMAC10.html)
CA (1) CA2714997A1 (cg-RX-API-DMAC10.html)
NZ (1) NZ588177A (cg-RX-API-DMAC10.html)
WO (1) WO2009124670A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107250378B (zh) * 2015-02-24 2021-09-03 特里奥科技株式会社 癌的脑转移的诊断、预防及治疗方法、以及用于通过血脑屏障的药物传输系统
WO2017222998A1 (en) 2016-06-20 2017-12-28 Beckman Coulter, Inc. Dry-down processes for dye-conjugated reagents
EP3746476A1 (en) 2018-01-31 2020-12-09 Alector LLC Anti-ms4a4a antibodies and methods of use thereof
EP3746484A4 (en) 2018-01-31 2021-11-17 Alector LLC ANTI-MS4A6A ANTIBODY AND METHOD OF USING THEREOF
PH12022550239A1 (en) * 2019-07-31 2022-12-19 Alector Llc Anti-ms4a4a antibodies and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10341812A1 (de) * 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung

Similar Documents

Publication Publication Date Title
Zhao et al. SNHG12 promotes angiogenesis following ischemic stroke via regulating miR-150/VEGF pathway
Pathak et al. Role of angiogenesis and its biomarkers in development of targeted tumor therapies
Guo et al. Exosomes: Potent regulators of tumor malignancy and potential bio-tools in clinical application
Shen et al. Post‐transcriptional regulation of the tumor suppressor miR‐139‐5p and a network of miR‐139‐5p‐mediated m RNA interactions in colorectal cancer
Wang et al. Targeting strategies on miRNA-21 and PDCD4 for glioblastoma
Yao et al. Down-regulation of Krüppel-like factor-4 by microRNA-135a-5p promotes proliferation and metastasis in hepatocellular carcinoma by transforming growth factor-β1
Choi et al. Interleukin-8 reduces post-surgical lymphedema formation by promoting lymphatic vessel regeneration
Matsumoto et al. Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma
Guo et al. miR-656 inhibits glioma tumorigenesis through repression of BMPR1A
Yu et al. Identification of a novel lincRNA‐p21‐miR‐181b‐PTEN signaling cascade in liver fibrosis
JP2014526456A5 (cg-RX-API-DMAC10.html)
Zhu et al. eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma
EP3111937A1 (en) Medicament for treatment of liver cancer
JP2016540778A5 (cg-RX-API-DMAC10.html)
CA2946407A1 (en) Multiple targeted rnai for the treatment of cancers
Han et al. TUG1 is involved in liver fibrosis and activation of HSCs by regulating miR-29b
Wang et al. Human cancer cells suppress behaviors of endothelial progenitor cells through miR-21 targeting IL6R
Zhang et al. Circ‐ACAP2 facilitates the progression of colorectal cancer through mediating miR‐143‐3p/FZD4 axis
EP3301176B1 (en) Method for identifying nucleic acids regulating metastasation
Hu et al. Interruption of the long non-coding RNA HOTAIR signaling axis ameliorates chemotherapy-induced cachexia in bladder cancer
JP2014523398A5 (cg-RX-API-DMAC10.html)
Zhou et al. Long noncoding RNA ZFAS1 promotes hepatocellular carcinoma proliferation by epigenetically repressing miR-193a-3p.
Zheng et al. Roles of cancer-associated fibroblast functional heterogeneity in shaping the lymphatic metastatic landscape: new insights and therapeutic strategies
Luo et al. The function and clinical relevance of lncRNA UBE2CP3-001 in human gliomas
Chen et al. MicroRNA-34a: role in cancer and cardiovascular disease